Joseph Eid Biography and Net Worth

As Head of Global Medical Affairs, Dr. Joseph Eid leads the company’s efforts to communicate the safe and appropriate utilization of its medicines to the medical community and gather insights on medical practices and patient needs from stakeholders. Internally, Joe’s organization also plays a critical role as the bridge between the drug development and commercial organizations.

“I’m passionate about bringing innovative treatments to patients and providing them with access as fast as possible,” says Joe. “Making that happen requires that all of the functions involved in drug discovery, development and commercialization keep the patient at the center of their discussions and plans at all times.”

Before joining BMS in 2017, Joe spent nine years at Merck, most recently as Head of Oncology Global Medical Affairs. Previously, he served in Merck Research Labs as Team Leader for the anti-PD-1 antibody program, where he managed the first-in-human trials and set the strategy leading to registration. Prior to joining Merck, he was Clinical Team Leader and Science Team Leader in Oncology Clinical Research at Hoffmann-La Roche AG.

Joe holds a medical degree from St. Joseph University School of Medicine in Beirut, Lebanon, and is board certified in Medical Oncology, Hematology and Internal Medicine. He completed his fellowship in Hematology and Medical Oncology at Rutgers-Robert Wood Johnson Medical School (RWJMS) and served on the RWJMS faculty as Assistant Professor of Medicine in the departments of Medicine, and Pathology and Laboratory Medicine.

What is Joseph Eid's net worth?: The estimated net worth of Joseph Eid is at least $467,033.72 as of May 10th, 2021. Mr. Eid owns 8,069 shares of Bristol-Myers Squibb stock worth more than $467,034 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Eid may own. Learn More about Joseph Eid's net worth.
How old is Joseph Eid?: Mr. Eid is currently 75 years old. There are 7 older executives and no younger executives at Bristol-Myers Squibb. Learn More on Joseph Eid's age.
How do I contact Joseph Eid?: The corporate mailing address for Mr. Eid and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Joseph Eid's contact information.
Has Joseph Eid been buying or selling shares of Bristol-Myers Squibb?: Joseph Eid has not been actively trading shares of Bristol-Myers Squibb over the course of the past ninety days. Most recently, Joseph Eid sold 1,118 shares of the business's stock in a transaction on Monday, May 10th. The shares were sold at an average price of $65.00, for a transaction totalling $72,670.00. Following the completion of the sale, the senior vice president now directly owns 8,069 shares of the company's stock, valued at $524,485. Learn More on Joseph Eid's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 6,901 shares worth more than $349,655.16. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 700 shares worth more than $38,934.00. The most recent insider tranaction occured on November, 4th when SVP Phil M Holzer sold 700 shares worth more than $38,934.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 11/4/2024.

Joseph Eid Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/10/2021	Sell	1,118	$65.00	$72,670.00	8,069
8/17/2020	Sell	5,327	$64.00	$340,928.00	2,534

Joseph Eid Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $58.28

$57.47

$58.30

50 Day Range

MA: $53.26

$48.25

$59.82

2 Week Range

Now: $58.28

$39.35

$61.08

Volume

2,581,383 shs

Average Volume

14,373,831 shs

Market Capitalization

$118.20 billion

P/E Ratio

N/A

Dividend Yield

4.12%

Beta

0.44

📉 Warning: Market Crash Predicted - Secure Your Savings

From Behind the Markets | Ad

The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.

Take these 4 steps to protect your retirement here >>>

Joseph Eid Biography and Net Worth

What is Joseph Eid's net worth?

How old is Joseph Eid?

How do I contact Joseph Eid?

Has Joseph Eid been buying or selling shares of Bristol-Myers Squibb?

Who are Bristol-Myers Squibb's active insiders?

Are insiders buying or selling shares of Bristol-Myers Squibb?